tacrolimus + mycophenolate mofetil + basiliximab + corticosteroids

This is a **combination immunosuppressive regimen** used primarily in solid organ transplantation, particularly for the prevention of rejection in kidney and liver transplant recipients. It consists of four agents: - **Tacrolimus**: a calcineurin inhibitor, inhibits T-lymphocyte activation by blocking calcineurin, reducing interleukin-2 transcription. - **Mycophenolate mofetil**: an antimetabolite, suppresses lymphocyte proliferation by inhibiting inosine monophosphate dehydrogenase, blocking de novo purine synthesis in T- and B-lymphocytes. - **Basiliximab**: a chimeric monoclonal antibody targeting the interleukin-2 receptor alpha chain (CD25) on activated T cells, preventing their proliferation. - **Corticosteroids**: synthetic adrenocortical steroids (e.g., prednisone, methylprednisolone, prednisolone) with broad immunosuppressive and anti-inflammatory activity, suppress multiple immune pathways by modulating gene transcription. This regimen is often referred to as a **quadruple immunosuppressive regimen** and is used for both induction and initial maintenance in organ transplantation, especially in patients at moderate or high risk for acute rejection. The inclusion of basiliximab provides targeted IL-2 receptor blockade during the critical early post-transplant period, while the other agents provide ongoing immunosuppressive effect. This approach aims for strong early immunosuppression, with possible minimization or withdrawal of corticosteroids in the maintenance phase.